Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes

Claudio Maffeis, Ivana Rabbone

Risultato della ricerca: Contributo su rivistaArticolo di reviewpeer review

Abstract

The pharmacokinetic and pharmacodynamic properties of the second-generation basal insulin glargine 300 Units/mL (Gla-300) may be of benefit in the treatment of type 1 diabetes mellitus (T1DM). Gla-300 provides a stable and sustained time-action profile, which is associated with glycaemic control and flexible dosing schedule. This review summarises the available evidence on the safety and efficacy of Gla-300 in children and adolescents with T1DM. Gla-300 is as effective as the first-generation basal insulin glargine 100 Units/mL (Gla-100), a standard of care for patients with diabetes in reducing HbA1c, and shows a lower risk of severe hypoglycaemia and hyperglycaemia in children and adolescents with T1DM. However, Gla-300 and Gla-100 are not bioequivalent and are not directly interchangeable. Real-world studies on patients aged 6–17 years are limited. To date, only one small study assessed the effectiveness and safety of Gla-300 versus Gla-100 in newly diagnosed T1DM paediatric patients, confirming the treatment safety and effectiveness of Gla-300 in clinical practice. Gla-300 is a longer-acting basal insulin alternative in the management of children (aged ≥ 6 years) and adolescents with T1DM.

Lingua originaleInglese
pagine (da-a)499-512
Numero di pagine14
RivistaPaediatric Drugs
Volume24
Numero di pubblicazione5
DOI
Stato di pubblicazionePubblicato - set 2022

Fingerprint

Entra nei temi di ricerca di 'Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes'. Insieme formano una fingerprint unica.

Cita questo